High Throughput Screening Market (2024-2031)
The High Throughput Screening Market was valued at $22.15 billion in 2023. This market is expected to reach $47.41 billion by 2031, from an estimated $24.18 billion in 2024, at a CAGR of 10.1% during the forecast period 2024-2031. High Throughput Screening Market Size & Forecast High throughput
- Published
- Mar 2024
- Pages
- 250
- Format
- PDF + Excel
- Report ID
- MRHC - 10443
- Base year
- 2023
- 2023 · BASELINE
- $22.15B
- 2031
- $47.41B
- CAGR 2024–2031
- 10.1%
2023 baseline · 2024–2031 forecast at 10.1% CAGR · hover a bar for the value
Key highlights
Based on Offerings, the Software & Services Segment is Projected to Register the Highest CAGR During the Forecast Period
Based on Technologies, in 2024, the Cell-based Assay Segment is Expected to Account for the Largest Share of the Market
Based on Applications, the Target Identification Segment is Expected to Account for the Largest Share of the Market
Based on End Users, the Pharmaceutical and Biotechnology Industry Segment is Expected to Account for the Largest Share of the Market
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | ~250 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 10.1% |
| Estimated Market Size (Value) | $47.41 billion by 2031 |
| Segments Covered | By Product · Cell-Based Assays · 2D Cell Culture · 3D Cell Culture · Scaffold Based Technology · Natural Polymer Hydrogels · Collagen · Gelatine · Hyaluronic Acid · Alginate · Synthetic Polymers · Solid Scaffolds · Scaffold Free Technology · Hanging Drop Plates · Microfluidics · Rotating Wall Vessel · Other Scaffold Free Technologies · Perfusion Cell Culture · Ultra-High Throughput Screening · Label-free Technology · Lab-on-Chip · (Note: Other scaffold-free technologies include pellet culture, liquid overlay, and spinning flask) · By Offerings · Consumables & Reagents · Instruments · Sample Preparation Instruments & Accessories · Liquid Handling Instruments · Readers · Other Instruments · Software & Services · (Note: Other instruments include laser scanning cytometers and microplate imagers) · By Application · Stem Cell Research · Toxicology Assessment · Target Identification · Primary Screening · By End User · Pharmaceutical and Biotechnology Companies · Academic and Research Institutes · Contract Research Organizations (CROs) |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa |
| Key Companies | Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Revvity Inc. (U.S.), Tecan Group Ltd. (Switzerland), Axxam S.p.A. (Italy), Charles River Laboratories International, Inc. (U.S.), Hamilton Company (U.S.), Promega Corporation (U.S.), and Aurora Biomed Inc. (Canada). |
Report overview
Segments covered: technology, offering, application, end user. Regions: North America, Europe, Asia-Pacific, Latin America.
High throughput screening (HTS) or high-throughput experimentation (HTE) is used to carry out many reactions simultaneously in parallel synthesis. HTS assays are specifically useful for efficient and rapid screening of compounds to find the ideal reactants for the reaction. High-throughput screening methods frequently use automated systems such as computer programs, robotic plating systems, and automated data collection/analysis for the identification of potential reactants. HTS has transformed the drug discovery process and is used by research laboratories, pharmaceutical companies, academic institutions, and other end users to identify new potential drug candidates.
Report infographic
Market dynamics
4 factors across 2 forcesIn June 2023,
the Commonwealth Government’s Medical Research Future Fund (MRFF) (Australia) invested USD 9.75 million to establish MedChem Australia, a new national medicinal chemistry initiative. This funding aims to accelerate the identification of early-stage drug candidates.
In July 2022,
the Council of Scientific and Industrial Research (CSIR) (India) invested USD 6.73 million in R&D activities for drug discovery and development.
In November 2021,
the Medical Research Agency (Poland) announced USD 73.3 million (PLN 300 million) in funding to help produce vaccines based on mRNA technology in Poland.
Table of contents
12 chapters · 116 sections · 250 pages · click to expandSegmental analysis
| Segment | Largest share (2024) | Fastest growth (2024–2031) |
|---|---|---|
| By Offering | — | Software & services |
| By Technology | Cell-based Assay | — |
| By Application | Target Identification | — |
| By End User | Pharmaceutical and Biotechnology Industry | — |
By Offering
- The software & services segment is expected to register the highest CAGR during the forecast period.
- The high CAGR of the segment is attributed to the increasing adoption of software for the data analysis obtained through the HTS.
- Additionally, HTS leverages the automation in instruments such as liquid handling systems, which require data processing software.
By Technology
- The Cell-based Assay Segment is Expected to Account for the Largest Share of the Market
- The cell-based assays segment is expected to account for the largest share of the high throughput screening market.
- The use of cell-based assays in drug-discovery screening applications and biomedical research to quantify off-target interactions, cytotoxicity, and biochemical mechanisms is attributed to the largest share of the segment.
- The benefits associated with high throughput cell-based assays, such as physiological relevance, generation of more data, and the ability to simultaneously measure compound characteristics, are also supporting the segment's large share.
By Application
- The target identification segment is expected to account for the largest share of the high throughput screening market.
- The large share of the segment is attributed to the increased adoption of high throughput products for the efficient, cost-effective, and accurate identification of targets in the early stage of drug discovery.
- Additionally, increasing drug failure rate during clinical trials due to drug toxicity and lack of drug efficacy is increasing the demand for target identification.
- Additionally, HTS is also used in cases where the structure information of the target molecule is not known, thus providing the flexibility of target identification from a large number of molecules.
By End User
- The Pharmaceutical and Biotechnology Industry Segment is Expected to Account for the Largest Share of the Market
- The pharmaceutical & biotechnology industry segment is expected to account for the largest share of the high throughput screening market.
- The large market share of this segment is attributed to the need to develop new therapies owing to increasing disease prevalence and increased spending on pharmaceutical R&D.
- For instance, global pharmaceutical R&D expenditure is expected to reach USD 213 billion in 2026 from USD 179 billion in 2020 (Source: International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)).
- Additionally, pharmaceutical & biotechnology companies' shift from traditional screening methods to HTS is contributing to the large share of the segment.
Geographic analysis
North America
Largest shareIn 2024, North America is expected to account for the largest share of the high throughput screening market. North America's significant market share is attributed to several factors, including substantial R&D investments by pharmaceutical and biotechnology companies for drug and biomarker development, a growing prevalence of chronic diseases, increased healthcare expenditure, the presence of key market players in the region, and government initiatives supporting research and development. The surge in R&D spending by pharmaceutical companies is anticipated to drive the demand for high throughput screening, driving the market. According to the European Federation of Pharmaceutical Industries and Associations (Belgium), in the U.S., the pharmaceutical R&D expenditure annual growth rate was 15.6% from 2018-2022 compared to 13.6% from 2013-2017. North America: Largest Regional Market
Competitive landscape
The report offers a competitive landscape based on an extensive assessment of the product offerings and geographic presence of leading market players and the key growth strategies adopted by them over the past few years 2020–2024. The key players operating in the global high throughput screening market are Thermo Fisher Scientific, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Merck KGaA (Germany), Danaher Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Revvity Inc. (U.S.), Tecan Group Ltd. (Switzerland), Axxam S.p.A. (Italy), Charles River Laboratories International, Inc. (U.S.), Hamilton Company (U.S.), Promega Corporation (U.S.), and Aurora Biomed Inc. (Canada).
- Thermo Fisher Scientific, Inc. (U.S.)
- Agilent Technologies, Inc. (U.S.)
- Merck KGaA · Germany
- Danaher Corporation (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Revvity Inc. (U.S.)
- Tecan Group Ltd. · Switzerland
- Axxam S.p.A · Italy
- Charles River Laboratories International, Inc. (U.S.)
- Hamilton Company (U.S.)
- Promega Corporation (U.S.)
- Aurora Biomed Inc. · Canada
Frequently asked questions
The global high throughput screening market covers the study of various technologies and offerings in HTS for multiple applications used across end users. This report also involves the analysis of various segments of high throughput screening at the regional and country levels.
Cite this report
Meticulous Research. (2024). High Throughput Screening Market - Global Opportunity Analysis and Industry Forecast (2024-2031) (Report No. MRHC - 10443). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/high-throughput-screening-market-3206